


heterocycloalkylalkyl, arylalkyl, heteroarylalkyl and acyl; each of which may be optionally substituted;

or a pharmaceutically acceptable salt or prodrug thereof, wherein when R is methyl or isopropyl methyl then R<sub>2</sub> is not benzyl.

In one preferred embodiment the present invention provides compounds having the Formula (2)



Formula (2)

wherein

R<sup>1</sup> is selected from the group consisting of H, C<sub>1</sub>-C<sub>6</sub> alkyl and acyl;

L is a single bond or is a C<sub>1</sub>-C<sub>5</sub> hydrocarbon chain which may contain 0 to 2 multiple bonds independently selected from double bonds and triple bonds and wherein, the chain may optionally be interrupted by at least one of -O-, -S-, -S(O)- and -S(O)<sub>2</sub>- and the chain may optionally be substituted with one or more substituents independently selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl;

Z is selected from the group consisting of a single bond, N(R<sup>1</sup>), O, S, S(O) and S(O)<sub>2</sub>;

A is selected from the group consisting of a single bond, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted cycloalkylene and optionally substituted heterocycloalkylene;

B is selected from the group consisting of a single bond, optionally substituted aminoacyl, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted arylalkylene, optionally substituted heteroarylalkylene, optionally substituted alkylarylene, optionally substituted alkylheteroarylene, optionally substituted C<sub>1</sub>-C<sub>3</sub> alkylene, optionally substituted heteroalkylene, optionally substituted cycloalkylene, optionally substituted heterocycloalkylene and optionally substituted -(CH<sub>2</sub>)<sub>m</sub>-C(O)-N(R<sup>4</sup>)-(CH<sub>2</sub>)<sub>n</sub>-, wherein n is an integer from 0 to 6, m is an integer from 0 to 6;